Navigation Links
Testosterone Cream – Ineffective in Enhancing Libido in Female Cancer Survivor

The much talked about testosterone cream for enhancing sexual desire in female cancer survivors did not prove very effective, a new study// conducted by Mayo clinic has shown.

A low sex drive is common in women cancer survivors. As an extension to a previous study which pointed a link between androgen therapy and increased sex drive in women with sufficient estrogen levels, this new study was conducted on 150 post menopausal cancer survivors.

The women were divided into two groups. One group got a testosterone cream and the other received a placebo for four weeks. For the ensuing four weeks, treatment was interchanged between the groups.

The groups had to answer a questionnaire in the beginning of the program and subsequently at four and eight weeks regarding their desire for sex. The finding revealed, there was no difference in libido between the two groups. Instead both groups showed a marginal increase in libido, portraying a placebo effect, rather than the effect of the testosterone cream.

Explaining that the ineffectiveness of the testosterone cream could be attributed to low estrogen levels among the women who took part in the study, researchers said, "If providing supplemental estrogen to women who are postmenopausal is required to obtain a benefit from androgen therapy, then it does not appear that androgen supplementation would be a viable option for women who must avoid (estrogen) replacement."

Page: 1

Related medicine news :

1. Testosterone Replacement Therapy Safe If Monitored Appropriately
2. Low Testosterone Levels the Cause Of Depression In Men
3. The Use Of Testosterone Replacement Therapy Questioned
4. Depression In Men Could Be To Low Testosterone Levels
5. Testosterone patch for women Rejected For safety Reasons
6. Testosterone Patches Found To Increase Sexual Desire In Menopausal Women
7. Testosterone Therapy can improve sexual function in postmenopausal women
8. Fatherhood Found To Tame Men by Reducing Testosterone Levels
9. Testosterone levels could serve as a marker for determining risk of SIDS
10. Males Lifespan Shortened By Elevated Levels Of Testosterone
11. Study Indicates An Increased Risk Of Breast Cancer In Women Undertaking Estrogen and Testosterone Therapy
Post Your Comments:

(Date:11/24/2015)... ... 24, 2015 , ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the ... , FDA has long asserted that design and manufacture of Laboratory Developed Tests ... do not meet the device regulations. , Come up short in an inspection and ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress and ... developer of renewable energy technologies capable of producing commercially useful amounts of thermal ... its WET™ and HHT™ Boiler System reactor core modules were presented to Congress ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... to share their knowledge and experiences at a live taping of the next ... Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University Hotel ...
(Date:11/24/2015)... ... 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse ... of the staff members at their recovery center. The videos highlight some of the ... of the things that make their recovery program so unique. , “Making the decision ...
(Date:11/24/2015)... ... ... Shoulder , LLC launched their Pro Vest, the latest version of their widely popular weight ... under 10 hours. , The campaign, which will continue to run through ... market. , The PRO Vest provides consumers with a less expensive, one-size fits all comfort ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Thanks to a donor ... St. Mary,s Medical Center,s Sister Diane Grassilli Center for ... capabilities in San Francisco . ... friend, stepped forward with a gift of $617,320 that ... Digital Mammography with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
(Date:11/24/2015)... --> --> ... by Product Type (Bone Graft, Bine Graft Substitute, Platelet Rich ... Lumbar Interbody Fusion), End User, and Geography - Global Forecast ... at $1.90 Billion in 2014 and is expected to reach ... the forecast period of 2015 to 2020. Browse ...
Breaking Medicine Technology: